China Resources Double Crane: The holding subsidiary Shuanghe Tianan Pharmaceuticals' Metformin Hydrochloride Sustained-release Tablets received the Drug Supplementary Application Approval Notice.

China Resources Shuanghe announced that its holding subsidiary, Shuanghe Tianan Pharmaceutical Co., Ltd., recently received the "Drug Supplement Application Approval Notice" for the approval of Pioglitazone hydrochloride dispersible tablets issued by the National Medical Products Administration. This drug is used for the treatment of type 2 diabetes. Shuanghe Tianan started consistency evaluation work in 2017, received the acceptance notice on December 20, 2024, and passed the consistency evaluation on November 21, 2025. As of the announcement date, the cumulative research and development investment is 8.8227 million yuan. The global sales of pioglitazone hydrochloride tablets are 254 million US dollars, with sales of "ACTOS" reaching 41.6958 million US dollars. In 2024, the total sales of pioglitazone hydrochloride tablets in the domestic medical and retail markets amounted to 349 million yuan.